The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1
Trial Snapshot
- Phase
- Phase 2
- Status
- Enrolling By Invitation
- Sponsor
- Enrollment
- 146
- Locations
- 1
- Primary Endpoint
- Disease progression
Study Overview
Brief Summary
The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of PSP.
Regimen A will evaluate the safety and efficacy of a single study drug, AADvac1, in participants with PSP.
Detailed Description
The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is designed as a perpetual platform trial. This means that there is a single Master Protocol dictating the conduct of the trial. The PTP Master Protocol is registered as NCT07173803. Once a participant enrolls into the Master Protocol and meets all eligibility criteria, the participant will be eligible to be randomized into any currently enrolling regimen. All participants will have an equal chance to be randomized to all regimens that are active at the time of screening. If a participant is randomized to Regimen A: AADvac1, participants will complete a baseline assessment and be randomized in a 3:1 ratio to either active AADvac1 or matching placebo.
Participants must first enroll into the Master Protocol and be eligible to participate in the Master Protocol before being able to be randomly assigned to Regimen A.
For a list of enrolling sites, please see the PTP Master Protocol under NCT07173803.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel assignment
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Eligibility Criteria
- Ages
- 41 Years to 86 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Clinical diagnosis of possible or probable PSP Richardson's Syndrome as defined by the 2017 Movement Disorder Society (MDS) criteria.
- Presence of PSP symptoms for ≤5 years at screening (based on the best judgment of the site PI).
- Mini-Mental State Examination (MMSE) score at screening of ≥25.
- Able to walk at least 10 steps with minimal assistance (e.g., one arm for safety, but not postural support).
- Stable doses of permitted medications as described per protocol for 30 days prior to screening.
- Resides at home or in the community (assisted living is acceptable).
- As assessed by the site PI, participant is likely to be able to comply with the protocol for the duration of the study, and has adequate vision, hearing (hearing aid permitted), and literacy (English or Spanish) sufficient for compliance with the required testing procedures.
Exclusion Criteria
- Females who are breastfeeding or pregnant (as documented by a urine pregnancy test) during screening, or plan to become pregnant during the study.
- Females of childbearing potential who did not use a highly effective method of contraception within 28 days of screening and/or are not willing to use a highly effective method of contraception for the duration of their participation in the study.
- Lacks good venous access such that multiple blood draws would be precluded.
- Weighs less than 40kg, or more than 136kg at screening.
- Blood transfusion within 4 weeks of screening.
- Contraindications to MRI studies, including metal (ferromagnetic) implants, a cardiac pacemaker that is not compatible with MRI, and/or severe claustrophobia.
- Screening MRI scan showing structural evidence of alternative pathology not consistent with PSP that could explain a substantial portion of the participant's symptoms as indicated by the central MRI read.
- Any unstable and/or clinically significant medical condition likely to hamper the evaluation of safety and/or efficacy of study drug (e.g., clinically significant reduction in serum B12 or folate levels, clinically significant abnormalities of thyroid function, stroke, or other cerebrovascular or cardiovascular conditions), as per the site PI's judgment.
- History of severe allergic reaction (e.g., anaphylaxis) including but not limited to: severe allergic reaction to previous vaccines, foods, and/or medications.
- Hospitalization within 30 days prior to screening or baseline.
- Infections or major surgical procedures within 3 months prior to screening, judged to be clinically significant by the site PI.
- Myocardial infarction within 1 year prior to baseline, unstable angina pectoris, symptomatic congestive heart failure.
- History of cancer within the past 5 years other than treated skin squamous cell carcinoma, basal cell carcinoma, and melanoma in-situ, localized prostate cancer not requiring treatment, or prostate or breast cancer, which have been fully removed and are considered cured.
- History or presence of immunological or inflammatory conditions, including neurological disorders, meningitis or meningoencephalitis.
- History or presence of epilepsy requiring ongoing use of antiepileptic medications. Antiepileptic medications are permitted for pain or psychiatric use per the protocol.
- DSM-5 criteria for drug or alcohol abuse or dependence currently met within the past 5 years.
- Clinically significant abnormal vital signs including sustained sitting blood pressure >160/100 mm Hg.
- Diabetes mellitus with hemoglobin A1c (HbA1c) levels of ≥8.0%.
- Known history of human immunodeficiency virus (HIV-1 or 2).
- Known history of acute/chronic hepatitis B or C unless treated curatively.
Arms & Interventions
Matching Placebo
Intervention: Matching Placebo (Biological)
AADvac1
Intervention: AADvac1 (Biological)
Outcomes
Primary Outcomes
Disease progression
Time Frame: 52 weeks
Change in disease severity as measured by the 15-item modified Progressive Supranuclear Palsy Rating Scale (mPSPRS-15) in which the minimum score is 0 and the maximum score is 52, with higher scores indicating a worse outcome.
Secondary Outcomes
- Disease progression(52 weeks)
- Experiences of daily living(52 weeks)
- Activities of daily living(52 weeks)
- Disease severity(52 weeks)
- Health-related quality of life(52 weeks)
- Brain volume(52 weeks)
- Neurodegeneration(52 weeks)
Investigators
Adam Boxer
Endowed Professor in Memory and Aging
University of California, San Francisco
Study Sites (1)
Identifiers
- NCT ID
- NCT07217665
- Other Study IDs
- ATRI-015-A, R01AG085029
Dates
- First Submitted
- (last year)
- First Posted
- (11 months ago)
- Primary Completion
- (in 3 years)
- Study Completion
- (in 3 years)
- Last Verified
- (12 months ago)
- Last updated
- (last month)
Regulatory & Sharing
- FDA Regulated Drug
- Yes
- FDA Regulated Device
- No
- IPD Sharing Plan
- Yes
- Has Results
- No